Randomized Double-Blind Placebo-Controlled Study of Olanzapine for Chemotherapy-Related Anorexia in Patients With Locally Advanced or Metastatic Gastric, Hepatopancreaticobiliary, and Lung Cancer

医学 奥氮平 内科学 厌食症 安慰剂 胃肠病学 化疗 食欲 恶病质 性能状态 体重增加 生活质量(医疗保健) 癌症 肿瘤科 精神分裂症(面向对象编程) 体重 病理 精神科 替代医学 护理部
作者
Lakshmi Sandhya,Nirmala Devi Sreenivasan,Luxitaa Goenka,Biswajit Dubashi,Smita Kayal,Solaiappan Manikandan,G. Ramkumar,Harichandrakumar Kt,Prasanth Ganesan
出处
期刊:Journal of Clinical Oncology [American Society of Clinical Oncology]
卷期号:41 (14): 2617-2627 被引量:44
标识
DOI:10.1200/jco.22.01997
摘要

PURPOSE Anorexia occurs in 30%-80% of patients with advanced malignancies, which may be worsened with chemotherapy. This trial assessed the efficacy of olanzapine in stimulating appetite and improving weight gain in patients receiving chemotherapy. METHODS Adults (≥18 years) with untreated, locally advanced, or metastatic gastric, hepatopancreaticobiliary (HPB), and lung cancers were randomly assigned (double-blind) to receive olanzapine (2.5 mg once a day for 12 weeks) or placebo along with chemotherapy. Both groups received standard nutritional assessment and dietary advice. The primary outcomes were the proportion of patients with weight gain > 5% and the improvement in appetite (assessed by the visual analog scale [VAS] and the Functional Assessment of Chronic Illness Therapy system of Quality-of-Life questionnaires Anorexia Cachexia subscale [FAACT ACS]). Secondary end points were change in nutritional status, quality of life (QOL), and chemotherapy toxicity. RESULTS We enrolled 124 patients (olanzapine, 63 and placebo, 61) with a median age of 55 years (18-78 years), of whom 112 (olanzapine, 58 and placebo, 54) were analyzable. The majority (n = 99, 80%) had metastatic cancer (gastric [n = 68, 55%] > lung [n = 43, 35%] > HPB [n = 13, 10%]). The olanzapine arm had a greater proportion of patients with a weight gain of > 5% (35 of 58 [60%] v 5 of 54 [9%], P < .001) and improvement in appetite by VAS (25 of 58 [43%] v 7 of 54 [13%], P < .001) and by FAACT ACS (scores ≥37:13 of 58 [22%] v 2 of 54 [4%], P = .004). Patients on olanzapine had better QOL, nutritional status, and lesser chemotoxicity. Side effects attributable to olanzapine were minimal. CONCLUSION Low-dose, daily olanzapine is a simple, inexpensive, well-tolerated intervention that significantly improves appetite and weight gain in newly diagnosed patients on chemotherapy.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
3秒前
高高发布了新的文献求助10
4秒前
又又岩发布了新的文献求助10
5秒前
qikkk应助冯昊采纳,获得10
5秒前
cctv18应助鲤鱼冰海采纳,获得10
6秒前
南宫古伦完成签到 ,获得积分10
8秒前
无限的可乐完成签到,获得积分10
8秒前
感动新烟发布了新的文献求助10
10秒前
10秒前
10秒前
qikkk完成签到,获得积分10
10秒前
10秒前
可靠代丝完成签到,获得积分10
10秒前
11秒前
FFF123发布了新的文献求助10
14秒前
宴之思完成签到,获得积分10
15秒前
15秒前
袁青欣完成签到 ,获得积分10
15秒前
杨嘟嘟完成签到,获得积分10
16秒前
Doctor Tang发布了新的文献求助10
17秒前
寒桥完成签到,获得积分10
19秒前
19秒前
Sor发布了新的文献求助10
20秒前
21秒前
沉默的砖头完成签到,获得积分20
21秒前
hygge发布了新的文献求助10
22秒前
研友_LpvQlZ完成签到,获得积分10
22秒前
Eve完成签到,获得积分20
24秒前
万能图书馆应助一九九七采纳,获得10
24秒前
恋风恋歌发布了新的文献求助10
25秒前
25秒前
科研通AI2S应助FG采纳,获得10
28秒前
yukikaze完成签到,获得积分10
29秒前
Jinna706完成签到,获得积分10
30秒前
31秒前
31秒前
32秒前
FG完成签到,获得积分10
32秒前
学子完成签到 ,获得积分10
32秒前
glxbg发布了新的文献求助10
32秒前
高分求助中
The late Devonian Standard Conodont Zonation 2000
Semiconductor Process Reliability in Practice 1500
Handbook of Prejudice, Stereotyping, and Discrimination (3rd Ed. 2024) 1200
Nickel superalloy market size, share, growth, trends, and forecast 2023-2030 1000
Smart but Scattered: The Revolutionary Executive Skills Approach to Helping Kids Reach Their Potential (第二版) 1000
Mantiden: Faszinierende Lauerjäger Faszinierende Lauerjäger 800
PraxisRatgeber: Mantiden: Faszinierende Lauerjäger 800
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3243630
求助须知:如何正确求助?哪些是违规求助? 2887516
关于积分的说明 8248754
捐赠科研通 2556147
什么是DOI,文献DOI怎么找? 1384291
科研通“疑难数据库(出版商)”最低求助积分说明 649827
邀请新用户注册赠送积分活动 625755